Palantir alumni raise $12M for AI platform targeting the full drug development lifecycle

What's the deal? Perceptic, an AI platform for drug discovery and development, has emerged from stealth with a $12M seed round led by Accel, Air Street CapitalDealroom has a profile for this one. Try Dealroom →, and Elder GullDealroom has a profile for this one. Try Dealroom →. Founded by the team behind Palantir's AIP product, it has already deployed its platform across multiple top-10 pharma companies, biotechs, and contract research organisations, including CSL.

Why now? Drug development has long suffered from fragmented data and siloed workflows — decades of proprietary research locked in systems that don't communicate. Most pharma AI efforts have targeted individual steps rather than the full lifecycle, leaving a gap Perceptic is moving to fill.

The company claims early results are significant: scientific due-diligence time cut from weeks to hours, asset screening scaled from hundreds per week to thousands per minute, and a 50-fold increase in clinical data extractions.

What could go wrong? Pharma is a notoriously slow-moving, heavily regulated industry. Convincing drug developers to consolidate critical decision-making into a single third-party platform raises real questions around data sovereignty, regulatory compliance, and institutional trust.

Perceptic's edge rests heavily on its founders' Palantir pedigree. If it struggles to replicate that enterprise credibility at scale, or if larger incumbents build competing unified platforms, its early-mover advantage could erode quickly.

The signal: Perceptic's launch reflects a broader shift in enterprise AI — from point-tool optimisation to system-level intelligence. The bet is that the next wave of value won't come from better individual models, but from platforms that connect data and decisions across entire workflows.

In pharma, where a single drug can take 15 years and billions of dollars to reach market, that compounding logic is especially powerful. If it works, Perceptic won't just speed up R&D — it could reshape how the industry allocates capital and makes bets.

A.M.